High Falls Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$607K Sell
565
-48
-8% -$45.9K 0.12% 55
2025
Q3
$467K Buy
613
+5
+0.8% +$3.72K 0.1% 75
2025
Q2
$474K Buy
608
+21
+4% +$16.3K 0.1% 67
2025
Q1
$485K Buy
587
+22
+4% +$18.3K 0.11% 65
2024
Q4
$436K Buy
565
+5
+0.9% +$4.14K 0.1% 70
2024
Q3
$496K Buy
560
+34
+6% +$30.6K 0.11% 63
2024
Q2
$476K Buy
526
+35
+7% +$28K 0.12% 62
2024
Q1
$382K Buy
+491
New +$349K 0.1% 75
2021
Q2
Sell
-2,010
Closed -$376K 121
2021
Q1
$376K Buy
+2,010
New +$393K 0.11% 82

Other funds holding LLY

High Falls Advisors's LLY Position: Q4 2025 in Review

High Falls Advisors reduced its Eli Lilly (LLY) stake by 7.8% in Q4 2025, selling an estimated $45.9K and leaving 565 shares worth $607K. The position accounts for 0.12% of the portfolio, ranked #55.

High Falls Advisors first reported a position in LLY in Q1 2021 and has held it in 9 quarters since. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

  • High Falls Advisors held 565 shares of Eli Lilly worth $607K as of Q4 2025.
  • High Falls Advisors sold 48 Eli Lilly shares in Q4 2025, an estimated $45.9K.
  • Eli Lilly made up 0.12% of High Falls Advisors's portfolio in Q4 2025, its #55 holding.
  • High Falls Advisors first reported a position in Eli Lilly in Q1 2021 and has held it in 9 quarters since.
  • 4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on High Falls Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.